Antin JH: Long-term care after hematopoietic-cell transplantation in adults. N Engl J Med 347:36–42, 2002.
Appelbaum FR, Forman SJ, Negrin RS, et al (eds): Hematopoietic Cell Transplantation. 4th ed. Malden, MA: Blackwell Science; 2009.
Brunstein CG, Fuchs EJ, Carter SL, et al: Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. Blood 118:282–288, 2011.
Brunstein CG, Gutman JA, Weisdorf DJ, et al: Allogeneic hematopoietic cell transplantation for hematological malignancy: Relative risks and benefits of double umbilical cord blood. Blood 116:4693–4699, 2010.
Cutler C, Kim HT, Ayanian S, et al: Prediction of veno-occlusive disease using biomarkers of endothelial injury. Biol Blood Marrow Transplant 16:1180–1185, 2010.
Cutler C, Miklos D, Kim HT, et al: Rituximab for steroid-refractory chronic graft-versus-host disease. Blood 108:756–762, 2006.
Deeg HJ, Sandmaier BM: Who is fit for allogeneic transplantation? Blood 116:4762–4770, 2010.
de Lima M, Giralt S: Allogeneic transplantation for the elderly patient with acute myelogenous leukemia or myelodysplastic syndrome. Semin Hematol 43:107–117, 2006.
Fröhling S, Schlenk RF, Breitruck J, et al: Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: A study of the AML Study Group Ulm. Blood 100:4372–4380, 2002.
Fung HC, Cohen S, Rodriguez R, et al: Reduced-intensity allogeneic stem cell transplantation for patients whose prior autologous stem cell transplantation for hematologic malignancy failed. Biol Blood Marrow Transplant 9:649–656, 2003.
Geisler CH, Kolstad A, Laurell A, et al: Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: A nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 112:2687–2693, 2008.
Harousseau JL, Moreau P: Evolving role of stem cell transplantation in multiple myeloma. Clin Lymphoma Myeloma 6:89–95, 2005.
Hertzberg M, Grigg A, Gottlieb D, et al: Reduced-intensity allogeneic haemopoietic stem cell transplantation induces durable responses in patients with chronic B-lymphoproliferative disorders. Bone Marrow Transplant 37:923–928, 2006.
Ho VT, Aldridge J, Kim HT, et al: Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and mini-methotrexate (Tac/Sir/MTX) as acute graft-versus-host disease prophylaxis after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 15:844–850, 2009.
Ito JI, Kriengkauykiat J, Dadwal SS, et al: Approaches to the early treatment of invasive fungal infection. Leuk Lymphoma 51:1623–1631, 2010.
Kanakry CG, Tsai HL, Bolaños-Meade J, et al: Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS. Blood 124:3817–3827, 2014.
Koreth J, Matsuoka K, Kim HT, et al: Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med 365:2055–2066, 2011.
Krishnan A, Nademanee A, Fung HC, et al: Phase II trial of transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin’s lymphoma. J Clin Oncol 26:90–95, 2008.
Laughlin MJ, Eapen M, Rubinstein P, et al: Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med 351:2265–2275, 2004.
Lavoie JC, Connors JM, Phillips GL, et al: High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: Long-term outcome in the first 100 patients treated in Vancouver. Blood 106:1473–1478, 2005.
Lokhorst H, Einsele H, Vesole D, et al: International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma. J Clin Oncol 28:4521–4530, 2010.
Loren AW, Chow E, Jacobsohn DA, et al: Pregnancy after hematopoietic-cell transplantation: A report from the late effects working committee of the Center for International Blood and Marrow Transplant Research (CIBMTR). Biol Blood Marrow Transplant 17:157–166, 2011.
Maloney DG, Molina AJ, Sahebi F, et al: Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 102:3447–3454, 2003.
Martin PJ, Counts GW Jr, Appelbaum FR, et al: Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation. J Clin Oncol 28:1011–1016, 2010.
Michallet M, Ito JI: Approaches to the management of invasive fungal infections in hematologic malignancy and hematopoietic cell transplantation. J Clin Oncol 27:3398–3409, 2009.
Nademanee A, Forman S, Molina A, et al: A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma. Blood 106:2896–2902, 2005.
Nakamura R, Forman SJ: Reduced intensity conditioning for allogeneic hematopoietic cell transplantation: Considerations for evidence-based GVHD prophylaxis. Expert Rev Hematol 7:407–421, 2014.
Oliansky DM, Czuczman M, Fisher RI, et al: The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of diffuse large B cell lymphoma: Update of the 2001 evidence-based review. Biol Blood Marrow Transplant 17:20–47, 2011.
Paczesny S, Choi SW, Ferrara JL: Acute graft-versus-host disease: New treatment strategies. Curr Opin Hematol 16:427–436, 2009.
Paschka P, Marcucci G, Ruppert AS, et al: Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): A Cancer and Leukemia Group B Study. J Clin Oncol 24:3904–3911, 2006.
Richardson PG, Soiffer RJ, Antin JH, et al: Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: A multicenter, randomized, dose-finding trial. Biol Blood Marrow Transplant 16:1005–1017, 2010.
Rodriguez R, Nakamura R, Palmer JM, et al: A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens. Blood 115:1098–1105, 2010.
Snyder DS, Palmer J, Gaal K, et al: Improved outcomes using tacrolimus/sirolimus for graft-versus-host disease prophylaxis with a reduced-intensity conditioning regimen for allogeneic hematopoietic cell transplant as treatment of myelofibrosis. Biol Blood Marrow Transplant 16:281–286, 2010.
Sun CL, Francisco L, Kawashima T, et al: Prevalence and predictors of chronic health conditions after hematopoietic cell transplantation: A report from the Bone Marrow Transplant Survivor Study. Blood 116:3129–3139, 2010.
Syrjala KL, Langer SL, Abrams JR, et al: Late effects of hematopoietic cell transplantation among 10-year adult survivors compared with case-matched controls. J Clin Oncol 23:6596–6606, 2005.
Tauro S, Craddock C, Peggs K, et al: Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia. J Clin Oncol 23:9387–9393, 2005.
Tuthill M, Chen F, Paston S, et al: The prevention and treatment of cytomegalovirus infection in haematopoietic stem cell transplantation. Cancer Immunol Immunother 58:1481–1488, 2009.
Vose JM, Carter S, Burns LJ, et al: Phase III randomized study of rituximab/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: Results from the BMT CTN 0401 trial. J Clin Oncol 31:1662–1668, 2013.
Wagner JE, Gluckman E: Umbilical cord blood transplantation: The first 20 years. Semin Hematol 47:3–12, 2010.
On HIV and HCT
Díez-Martín JL, Balsalobre P, Re A, et al; European Group for Blood and Marrow Transplantation Lymphoma Working Party: Comparable survival between HIV+ and HIV- non-Hodgkin and Hodgkin lymphoma patients undergoing autologous peripheral blood stem cell transplantation. Blood 113:6011–6014, 2009.
Durand C, Ambinder R, Blankson J, Forman S: HIV-1 and hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 18(1 Suppl):S172–S176, 2012.
Hütter G, Nowak D, Mossner M, et al: Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med 360:692–698, 2009.
Krishnan A, Molina A, Zaia J, et al: Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas. Blood 105:874–878, 2005.